Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
JIUYUAN GENE (02566.HK) JY54 Injection Approved to Commence Clinical Trials
Recommend 1 Positive 0 Negative 0 |
||||
|
||||
|
JIUYUAN GENE (02566.HK) announced that its self-developed JY54 injection has been approved by the National Medical Products Administration of China to commence clinical trials. JY54 exerts multiple biological effects by mimicking the mechanism of natural amylin and binding to amylin receptors, including inhibiting glucagon secretion, delaying gastric emptying and reducing appetite. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
